Website Search
Find information on spaces, staff, and services.
Catalog Search
Videos, Slides, Films
Pricing, reimbursement and market access issues in the United States and Europe
- Author / Creator
- Available as
- Online
Details
- Creator
- Lee Blansett
- Format
- Videos, Slides, Films
- Language
- English
- Publication
-
- London : Henry Stewart Talks, 2009
- Series
- Physical Details
-
- 1 videorecording (53 min., 58 sec.) : sound, color
- video file
- Retrieved March 7, 2024, from https://hstalks.com/bs/1074/.
- Introduction (1) -- Introduction (2) -- Introduction (3) -- Current and future reimbursement mechanisms -- Price, reimbursement and health economics -- Who is paying the bill -- Reimbursement of new drugs - a pricing issue -- The dynamic of price vs. reimbursement -- Payers are exploring ways of reducing costs -- Efficacy, safety and quality - no longer sufficient -- Achieving market access was a "negotiation" -- Increasing data and evidence is demanded -- EU states have mechanisms to control budget -- Measuring "value" is challenging -- Pharmacoeconomics - attempting to quantify value -- Quality adjusted life year (QALY) -- A new drug value and its adoption can vary -- Delays between authorisation and market access -- The future for payers? (1) -- The future for payers? (2) -- Who will fund incremental improvement? -- The future for pharmaceuticals? -- Politics and ethics will drive future reimbursements -- Who is paying in developed/developing countries -- The future will be shaped by political decisions -- The current political vision is not black and white -- Introduction: Lee Blansett -- Structures and philosophies differ -- Fragmented health funding -- Spending growth is cyclical -- Part D raises federal Rx spend -- U.S. expenditures twice EU levels -- Many players in 4th hurdle -- Private payers shift costs -- Formularies enable negotiation -- Fourth tiers shift high costs -- Cost sharing drives prescribing -- So, what's next in the U.S.? -- Scattered signs of pressure -- Generics ease pricing pressure -- Risk of federal negotiations -- A vague road to value -- We'll know value when we see it? -- Plans' prayers answered? -- Biomarkers' use inconsistent -- Value-based pricing clear? -- Conclusions -- Acknowledgements